Reduction in Oregon's Medication Dosing Visits After the SARS-CoV-2 Relaxation of Restrictions on Take-home Medication. McIlveen, J. W., Hoffman, K., Priest, K. C., Choi, D., Korthuis, P. T., & McCarty, D. J Addict Med, 15(6):516–518, December, 2021. doi abstract bibtex To slow the spread of SARS-CoV-2 in opioid treatment programs (OTPs), SAMHSA notified State Opioid Treatment Authorities that stable patients could receive up to 27 days of take-homes, less stable patients could receive up to 13 days with fewer take-homes for other patients. An analysis assessed how the relaxed standards affected the number of patient dosing visits and the amount of take-home medications dispensed in Oregon's 20 public, nonprofit, and for-profit OTPs. OTPs reported the number of patients receiving take homes pre and post federal policy change at 3 time points: pre SARS-CoV-2 (February or first half of March), post 1 SARS-CoV-2 (March, April, or May), and post 2 SARS-CoV-2 (April, May, or June). The patients receiving each quantity of take-homes were counted and means calculated for visits and take-homes per patient per month. A negative binomial mixed-effects regression model assessed change in mean dosing visits per patient. During the pre SARS-CoV-2 period, OTPs served 7792 patients monthly with 120,513 medication visits and dispensed 44,883 take-home doses. Mean patient visits per month were 15.5 with 5.8 take-homes per patient per month. Following the policy change, medication visits declined 33% and take-home medication increased 97% with 10.4 mean visits per patient and 11.3 mean take-homes per patient. The negative binomial mixed-effects regression model estimated a 54% reduction in mean visits per patient. The policy change had the intended effect. More research is needed to assess unintended consequences associated with increased access to take-home medication.
@article{mcilveen_reduction_2021,
title = {Reduction in {Oregon}'s {Medication} {Dosing} {Visits} {After} the {SARS}-{CoV}-2 {Relaxation} of {Restrictions} on {Take}-home {Medication}},
volume = {15},
issn = {1935-3227 (Electronic) 1932-0620 (Linking)},
doi = {10.1097/ADM.0000000000000812},
abstract = {To slow the spread of SARS-CoV-2 in opioid treatment programs (OTPs), SAMHSA notified State Opioid Treatment Authorities that stable patients could receive up to 27 days of take-homes, less stable patients could receive up to 13 days with fewer take-homes for other patients. An analysis assessed how the relaxed standards affected the number of patient dosing visits and the amount of take-home medications dispensed in Oregon's 20 public, nonprofit, and for-profit OTPs. OTPs reported the number of patients receiving take homes pre and post federal policy change at 3 time points: pre SARS-CoV-2 (February or first half of March), post 1 SARS-CoV-2 (March, April, or May), and post 2 SARS-CoV-2 (April, May, or June). The patients receiving each quantity of take-homes were counted and means calculated for visits and take-homes per patient per month. A negative binomial mixed-effects regression model assessed change in mean dosing visits per patient. During the pre SARS-CoV-2 period, OTPs served 7792 patients monthly with 120,513 medication visits and dispensed 44,883 take-home doses. Mean patient visits per month were 15.5 with 5.8 take-homes per patient per month. Following the policy change, medication visits declined 33\% and take-home medication increased 97\% with 10.4 mean visits per patient and 11.3 mean take-homes per patient. The negative binomial mixed-effects regression model estimated a 54\% reduction in mean visits per patient. The policy change had the intended effect. More research is needed to assess unintended consequences associated with increased access to take-home medication.},
number = {6},
journal = {J Addict Med},
author = {McIlveen, J. W. and Hoffman, K. and Priest, K. C. and Choi, D. and Korthuis, P. T. and McCarty, D.},
month = dec,
year = {2021},
pmcid = {PMC8339128},
keywords = {*SARS-CoV-2, *covid-19, Analgesics, Opioid, Humans, Oregon},
pages = {516--518},
}
Downloads: 0
{"_id":"TQCLNpFDBtPfspqfd","bibbaseid":"mcilveen-hoffman-priest-choi-korthuis-mccarty-reductioninoregonsmedicationdosingvisitsafterthesarscov2relaxationofrestrictionsontakehomemedication-2021","author_short":["McIlveen, J. W.","Hoffman, K.","Priest, K. C.","Choi, D.","Korthuis, P. T.","McCarty, D."],"bibdata":{"bibtype":"article","type":"article","title":"Reduction in Oregon's Medication Dosing Visits After the SARS-CoV-2 Relaxation of Restrictions on Take-home Medication","volume":"15","issn":"1935-3227 (Electronic) 1932-0620 (Linking)","doi":"10.1097/ADM.0000000000000812","abstract":"To slow the spread of SARS-CoV-2 in opioid treatment programs (OTPs), SAMHSA notified State Opioid Treatment Authorities that stable patients could receive up to 27 days of take-homes, less stable patients could receive up to 13 days with fewer take-homes for other patients. An analysis assessed how the relaxed standards affected the number of patient dosing visits and the amount of take-home medications dispensed in Oregon's 20 public, nonprofit, and for-profit OTPs. OTPs reported the number of patients receiving take homes pre and post federal policy change at 3 time points: pre SARS-CoV-2 (February or first half of March), post 1 SARS-CoV-2 (March, April, or May), and post 2 SARS-CoV-2 (April, May, or June). The patients receiving each quantity of take-homes were counted and means calculated for visits and take-homes per patient per month. A negative binomial mixed-effects regression model assessed change in mean dosing visits per patient. During the pre SARS-CoV-2 period, OTPs served 7792 patients monthly with 120,513 medication visits and dispensed 44,883 take-home doses. Mean patient visits per month were 15.5 with 5.8 take-homes per patient per month. Following the policy change, medication visits declined 33% and take-home medication increased 97% with 10.4 mean visits per patient and 11.3 mean take-homes per patient. The negative binomial mixed-effects regression model estimated a 54% reduction in mean visits per patient. The policy change had the intended effect. More research is needed to assess unintended consequences associated with increased access to take-home medication.","number":"6","journal":"J Addict Med","author":[{"propositions":[],"lastnames":["McIlveen"],"firstnames":["J.","W."],"suffixes":[]},{"propositions":[],"lastnames":["Hoffman"],"firstnames":["K."],"suffixes":[]},{"propositions":[],"lastnames":["Priest"],"firstnames":["K.","C."],"suffixes":[]},{"propositions":[],"lastnames":["Choi"],"firstnames":["D."],"suffixes":[]},{"propositions":[],"lastnames":["Korthuis"],"firstnames":["P.","T."],"suffixes":[]},{"propositions":[],"lastnames":["McCarty"],"firstnames":["D."],"suffixes":[]}],"month":"December","year":"2021","pmcid":"PMC8339128","keywords":"*SARS-CoV-2, *covid-19, Analgesics, Opioid, Humans, Oregon","pages":"516–518","bibtex":"@article{mcilveen_reduction_2021,\n\ttitle = {Reduction in {Oregon}'s {Medication} {Dosing} {Visits} {After} the {SARS}-{CoV}-2 {Relaxation} of {Restrictions} on {Take}-home {Medication}},\n\tvolume = {15},\n\tissn = {1935-3227 (Electronic) 1932-0620 (Linking)},\n\tdoi = {10.1097/ADM.0000000000000812},\n\tabstract = {To slow the spread of SARS-CoV-2 in opioid treatment programs (OTPs), SAMHSA notified State Opioid Treatment Authorities that stable patients could receive up to 27 days of take-homes, less stable patients could receive up to 13 days with fewer take-homes for other patients. An analysis assessed how the relaxed standards affected the number of patient dosing visits and the amount of take-home medications dispensed in Oregon's 20 public, nonprofit, and for-profit OTPs. OTPs reported the number of patients receiving take homes pre and post federal policy change at 3 time points: pre SARS-CoV-2 (February or first half of March), post 1 SARS-CoV-2 (March, April, or May), and post 2 SARS-CoV-2 (April, May, or June). The patients receiving each quantity of take-homes were counted and means calculated for visits and take-homes per patient per month. A negative binomial mixed-effects regression model assessed change in mean dosing visits per patient. During the pre SARS-CoV-2 period, OTPs served 7792 patients monthly with 120,513 medication visits and dispensed 44,883 take-home doses. Mean patient visits per month were 15.5 with 5.8 take-homes per patient per month. Following the policy change, medication visits declined 33\\% and take-home medication increased 97\\% with 10.4 mean visits per patient and 11.3 mean take-homes per patient. The negative binomial mixed-effects regression model estimated a 54\\% reduction in mean visits per patient. The policy change had the intended effect. More research is needed to assess unintended consequences associated with increased access to take-home medication.},\n\tnumber = {6},\n\tjournal = {J Addict Med},\n\tauthor = {McIlveen, J. W. and Hoffman, K. and Priest, K. C. and Choi, D. and Korthuis, P. T. and McCarty, D.},\n\tmonth = dec,\n\tyear = {2021},\n\tpmcid = {PMC8339128},\n\tkeywords = {*SARS-CoV-2, *covid-19, Analgesics, Opioid, Humans, Oregon},\n\tpages = {516--518},\n}\n\n\n\n\n\n\n\n","author_short":["McIlveen, J. W.","Hoffman, K.","Priest, K. C.","Choi, D.","Korthuis, P. T.","McCarty, D."],"key":"mcilveen_reduction_2021","id":"mcilveen_reduction_2021","bibbaseid":"mcilveen-hoffman-priest-choi-korthuis-mccarty-reductioninoregonsmedicationdosingvisitsafterthesarscov2relaxationofrestrictionsontakehomemedication-2021","role":"author","urls":{},"keyword":["*SARS-CoV-2","*covid-19","Analgesics","Opioid","Humans","Oregon"],"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://bibbase.org/zotero-group/Sierramatice/2808357","dataSources":["hF4cB9z6ogae2WwKD","wPp9MbcfArPrcn3De","3wdaKc5dBzq6bPRq5"],"keywords":["*sars-cov-2","*covid-19","analgesics","opioid","humans","oregon"],"search_terms":["reduction","oregon","medication","dosing","visits","sars","cov","relaxation","restrictions","take","home","medication","mcilveen","hoffman","priest","choi","korthuis","mccarty"],"title":"Reduction in Oregon's Medication Dosing Visits After the SARS-CoV-2 Relaxation of Restrictions on Take-home Medication","year":2021}